

Barbara Melosky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8553206/publications.pdf>

Version: 2024-02-01

42
papers

948
citations

394421

19
h-index

454955

30
g-index

43
all docs

43
docs citations

43
times ranked

1577
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping childcare support for patients at a sample of North American hospitals and cancer centers: an environmental scan. <i>Supportive Care in Cancer</i> , 2022, 30, 593-601.	2.2	1
2	Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 7-18.	3.8	57
3	Immunotherapy in Thoracic Malignancies: New Treatment and New Hope. <i>Current Oncology</i> , 2022, 29, 834-836.	2.2	0
4	A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib. <i>Current Oncology</i> , 2022, 29, 848-852.	2.2	6
5	Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. <i>Clinical Lung Cancer</i> , 2022, 23, 320-332.	2.6	5
6	Comparison of two-weekly versus four-weekly durvalumab consolidation for advanced NSCLC treated with chemoradiotherapy: a brief report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100316.	1.1	3
7	Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-world Standard of Care in Patients With BRAF-Mutated Advanced Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100324.	1.1	0
8	The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis. <i>Current Oncology</i> , 2022, 29, 2630-2643.	2.2	2
9	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4981-4997.	2.2	14
10	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	2.2	31
11	A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model". <i>Lung Cancer</i> , 2021, 151, 110-111.	2.0	0
12	EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. <i>Future Oncology</i> , 2021, 17, 2395-2408.	2.4	17
13	High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1850-1858.	1.1	25
14	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 136-151.	2.0	40
15	Immunotherapy in the First-Line Setting in Wild-Type NSCLC. <i>Current Oncology</i> , 2021, 28, 4457-4470.	2.2	10
16	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110563.	3.2	6
17	EGFR Point of Care Clinical Testing using Idylla Platform Decreases Laboratory Turnaround Time in Advanced Stage Non-Small Cell Lung Cancer, as Compared to New Generation Sequencing. <i>Journal of Medical & Radiation Oncology</i> , 2021, 1, 35-40.	0.0	0
18	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. <i>Current Oncology</i> , 2021, 28, 5278-5294.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 64-77.	3.7	30
20	Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. <i>Lung Cancer</i> , 2020, 139, 185-194.	2.0	11
21	Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 981-992.	3.7	23
22	Reducing time from colon cancer surgery to initiation of adjuvant chemotherapy: pilot project. <i>Canadian Journal of Surgery</i> , 2020, 63, E223-E225.	1.2	3
23	PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 1-5.	2.0	27
24	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 259-267.	2.0	28
25	Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, e576-e583.	2.6	32
26	Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. <i>Lung Cancer</i> , 2019, 133, 48-55.	2.0	19
27	Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). <i>Lung Cancer</i> , 2019, 127, 103-111.	2.0	57
28	Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. <i>Cancer Treatment Reviews</i> , 2018, 65, 65-77.	7.7	33
29	Bevacizumab biosimilars: scientific justification for extrapolation of indications. <i>Future Oncology</i> , 2018, 14, 2507-2520.	2.4	32
30	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. <i>Clinical Lung Cancer</i> , 2018, 19, 42-50.	2.6	6
31	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I—Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 17-25.	2.5	34
32	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 26-34.	2.5	30
33	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 38.	2.8	14
34	Low Grade Neuroendocrine Tumors of the Lung. <i>Frontiers in Oncology</i> , 2017, 7, 119.	2.8	12
35	Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 810-815.	1.6	79
36	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. <i>Journal of Clinical Oncology</i> , 2016, 34, 1676-1688.	1.6	71

#	ARTICLE	IF	CITATIONS
37	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 25-30.	2.3	14
38	Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR TKIs. <i>Frontiers in Oncology</i> , 2014, 4, 238.	2.8	63
39	Referral patterns in advanced non-small cell lung cancer: Impact on delivery of treatment and survival in a contemporary population based cohort. <i>Lung Cancer</i> , 2014, 86, 344-349.	2.0	23
40	Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. <i>Frontiers in Oncology</i> , 2014, 4, 244.	2.8	55
41	Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 256.	2.8	21
42	A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. <i>Lung Cancer</i> , 2014, 83, 73-77.	2.0	9